Future clinical studies are needed to evaluate HMGB1/TIM‐3 and CD47/SIRPα axes for potential immunotherapy targets, alone or in combination with chemotherapy, in NEC‐GYN. This evidence concerns the gene HAVCR2 and neuroendocrine carcinoma.